The Evolution of Vitiligo Treatment: From Steroids and Broad Immunosuppression to Targeted JAK Inhibition
When Maui, HI-based Dermatologist George Martin, MD, first started out in 1985, vitiligo was considered an orphan disease, but times have changed. “The evolution over the past 40-plus years has been nothing but astounding,” he says in this episode of Prescribing Hope in Vitiligo. Calling the development and approval of topical ruxolitinib (Opzelura, Incyte) for vitiligo, a “total game-changer” and proof that the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway was a major player in the pathogenesis of vitiligo, Dr. Martin discusses the importance of managing patient expectations during the repigmentation process.
About This Educational Video Series
This educational video series provides expert commentary on the current treatment landscape for patients with vitiligo.